

GRM4 RABBIT PAB

Cat.#: S219833

Product Name: Anti-GRM4 Rabbit Polyclonal Antibody

Synonyms: mGlu4, GPRC1D, MGLUR4

UNIPROT ID: Q14833 (Gene Accession - NP_000832)

Background: L-glutamate is the major excitatory neurotransmitter in the central nervous system and activates both ionotropic and metabotropic glutamate receptors. Glutamatergic neurotransmission is involved in most aspects of normal brain function and can be perturbed in many neuropathologic conditions. The metabotropic glutamate receptors are a family of G protein-coupled receptors, that have been divided into 3 groups on the basis of sequence homology, putative signal transduction mechanisms, and pharmacologic properties. Group I includes GRM1 and GRM5 and these receptors have been shown to activate phospholipase C. Group II includes GRM2 and GRM3 while Group III includes GRM4, GRM6, GRM7 and GRM8. Group II and III receptors are linked to the inhibition of the cyclic AMP cascade but differ in their agonist selectivities. Several transcript variants encoding different isoforms have been found for this gene.

Immunogen: Synthetic peptide of human GRM4

Applications: ELISA, IHC

Recommended Dilutions: IHC: 25-100; ELISA: 1000-5000

Host Species: Rabbit

Clonality: Rabbit Polyclonal

Isotype: Immunogen-specific rabbit IgG


Purification: Antigen affinity purification

Species Reactivity: Human, Mouse, Rat


Constituents: PBS (without Mg²⁺ and Ca²⁺), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

Research Areas: Signal Transduction, Neuroscience

Storage & Shipping: Store at -20°C. Avoid repeated freezing and thawing



Immunohistochemistry analysis of paraffin embedded Human breast cancer tissue using 219833(GRM4 Antibody) at a dilution of 1/15(cytoplasm, Nucleus).



In comparison with the IHC on the left, the same paraffin-embedded Human breast cancer tissue is first treated with the synthetic peptide and then with 219833(Anti-GRM4 Antibody) at dilution 1/15.



Product Description

Pioneering GTPase and Oncogene Product Development since 2010
